DelveInsight launched a new report on “Lupus Nephritis – Epidemiology Forecast to 2030”.
DelveInsight’s ‘Lupus Nephritis – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the facts of the report
1. As per DelveInsight analysis, the United Sates accounted for the maximum number of LN patients with 134,190 cases in 2017.
2. As per DelveInsight analysis, Italy accounted for 134,190 LN patients in 2017.
3. DelveInsight estimates, in 2017, Proteinuria associated with LN cases were found in all of the diagnosed cases, while second common manifestation in LN was microscopic hematuria with 85,882 cases (80%).
4. As per DelveInsight’s estimates, total Prevalent population of Lupus Nephritis in the 7 major markets was 190,819 in 2017,
“According to Delveinsight, Market Size of Lupus Nephritis (LN) in the 7MM was found to be $1360million in 2017.” Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is being characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.
The primary pathological findings in patients with SLE include inflammation, vasculitis, immune complex deposition, and vasculopathy.
Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.
Although LN can occur during a flare of SLE with skin manifestations or other organ system involvement, it often occurs without other clinical signs of active lupus. Thus, it is of key importance that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the location of deposition, and therefore, leads to differences in classification (mesangial, focal, diffuse).
Request for sample pages : https://delveinsight.com/sample-request/lupus-nephritis-epidemiology-forecast
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Lupus Nephritis – Pipeline Insights, 2020
The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
Lupus Nephritis- Market Insight, Epidemiology and Market Forecast -2030
The Lupus Nephritis market report provides current treatment practices, emerging drugs, Lupus Nephritis market share of the individual therapies, current and forecasted Lupus Nephritis market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/